DSM to acquire Glycom to accelerate growth in Early Life Nutrition
DSM to acquire world's leading supplier of Human Milk Oligosaccharides (HMO) for early life nutrition applications.
21 Feb 2020
DSM at a glance
Overview of our business & performance
2018 Integrated Annual Report
Strong progress on People, Planet and Profit
Why invest in DSM?
Our investor proposition
Growth & Value: Purpose-led, Performance-driven
Our ambitious financial targets
- at-a-glance
- annual-report-2018
- why-invest
- strategy
Key facts & figures
Royal DSM is a global purpose-led, science-based company in Nutrition, Health and Sustainable Living. DSM’s purpose is to create brighter lives for all. With its products and solutions DSM addresses some of the world’s biggest challenges whilst creating simultaneously economic, environmental and societal value for all its stakeholders; customers, employees, shareholders, and society-at-large. DSM delivers innovative solutions for human nutrition, animal nutrition, personal care and aroma, medical devices, green products and applications, and new mobility and connectivity. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 23,000 employees. The company was founded in 1902 and is listed on Euronext Amsterdam.
A broad, global nutrition business and a focused, high-quality, specialty materials portfolio
~€10b
Sales per year
~70%
In nutrition
~20%
Sales from innovation
~23,000
Employees
- NUTRITION
- MATERIALS
Nutrition
We provide nutritional solutions for animal health and human well-being, serving the global feed, food & beverage, pharmaceutical, infant nutrition, dietary supplements and personal care industries.
Animal Nutrition & Health
2019
Sales: ↑€2,892 (2018: €2,749)
Organic Growth: ↑4%
Volume Growth: ↑2%
Price Growth: ↑2%
Human Nutrition
2019
Sales: ↑€2,046 (2018: €1,989)
Organic Growth: ↓1%
Volume Growth: ↑2%
Price Growth: ↓3%
Sales1
€6,028m
Adjusted EBITDA1
€1,250M
Adjusted EBITDA Margin1
20.7%
1) Underlying business, net of temporary vitamin effect
Materials
Advanced and high-performance materials for the electrical & electronics, automotive, packaging, consumer goods, life protection, transportation and telecom industries.
Sales
€2,746M
Adjusted EBITDA
€509M
Adjusted EBITDA Margin
18.5%
Key facts 2018
We're a global leader in nutrition, active over full value chains serving local markets in 60 countries. Our unique and diverse portfolio combined with transformatinal capability enable us to the capability to respond to market needs, communities and people.
People 2018
Workforce
20,977
Year end 2018, excl. affiliates (~23,000 incl. affiliates)
Engagement
76%
Employee engagement favorable score (75% in 2017)
Gender ratio
28/72
Female/male ratio (27/73 in 2017)
Safety
0.33
Frequency Index of Recordable Injuries per 100 employees & contractors (0.36 in 2017)
Female exec.
19%
Female executives (17% in 2017)
Planet 2018
Greenhouse gasses
33%
GHG efficiency improvement v. 2008 baseline (2017: 26%)
Renewable Electricity
41%
Purchased electricity from renewable sources (21% in 2017)
Energy Efficiency
5.1%
Energy efficiency improvement v. 2015 baseline (2017: 3.8%)
Water Consumption
22
Water consumption in million m3 (2017: 23)
Innovation Sales
19%
Innovation sales (ambition ~20%)
Profit 2018
Net
Sales1
€8,852M
2017: €8,632
Adjusted EBITDA1
€1,532M
2017: €1,445
Adj EBITDA
Growth1
+6%
2017: 26%
ROCE
Growth1
+100
in bps
ROCE1
%
13.3%
2017: 12.3%
Cash
Provided1
€1,126M
2017: €996m
Net
Debt
€113M
2017: €742m
Net
Profit
€1,077M
2017: €1,781m
Net
Earnings2
€6.10
2017: €10.073
Proposed Dividend4
€2.30
2017: €1.85
1) Excluding temporary vitamin effect
2) Including temporary vitamin effect
3) Including gain of €1,250 million on Patheon disposal
4) Subject to approval by the Annual General Meeting of Shareholders
Latest financial & regulatory news
-
-
DSM - repurchase of shares (10-14 February 2020)
DSM repurchased 80,423 shares from 10 to 14 February 2020 at an average price of €116.31.
18 Feb 2020
-
DSM reports 2019 results
DSM delivered a good financial performance for the year and achieved the key milestones in the first year of its Strategy 2021.
13 Feb 2020
Leadership team
Geraldine Matchett
Co-CEO & Member of the Managing Board
Geraldine Matchett (1972, British; French; Swiss) is Co-Chief Executive Officer & Chief Financial Officer and Member of the Managing Board of Royal DSM. She was appointed as Co-CEO on 15 February 2020. Geraldine joined DSM’s Managing Board in August 2014 and became CFO on 1 December 2014. Her current term will end in 2022.
Dimitri de Vreeze
Co-CEO & Member of the Managing Board
Dimitri de Vreeze is Co-Chief Executive Officer & Chief Operating Officer and Member of the Managing Board of Royal DSM. He was appointed as Co-CEO on 15 February 2020 and joined DSM’s Managing Board in 2013. His current term will end in 2021.
- gm
- ddv
Read more
-
Why invest in DSM
DSM is positioned to drive continued above market organic growth and deliver further improvement in profitability, shareholder return and sustainability as we execute Strategy 2021.
-
Factbooks
An introduction for investors and analysts to DSM, our Nutrition, Materials and Innovation Center clusters and our businesses.
-
Share performance
DSM's share performance in real time and historically.